Ivan Biglang Awa
Acute Care · New York, NYNPI 1538803952
Payments from drug & device makers
Across 73 payments — averaging $38.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$579
- AstraZeneca$438
- Seagen Inc.$266
- AbbVie$261
- GT Medical Technologies, Inc$152
- Stemline Therapeutics Inc.$141
- plus $946 from 16 others
What the payments were for
- Food & beverage$2,58493%
- Education$1987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 21 | $579 |
| AstraZeneca(2 entities) | 7 | $438 |
| Seagen Inc. | 3 | $266 |
| AbbVie | 8 | $261 |
| GT Medical Technologies, Inc | 1 | $152 |
| Stemline Therapeutics Inc. | 1 | $141 |
| GSK | 7 | $138 |
| UCB, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $119 |
| Novartis | 5 | $81 |
| Johnson & Johnson | 3 | $68 |
| Pfizer | 3 | $60 |
| Eisai Inc. | 2 | $44 |
| Gilead | 1 | $31 |
| Bristol Myers Squibb | 1 | $26 |
| Puma Biotechnology, Inc. | 1 | $25 |
| Genmab U.S., Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Immunogen, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,782 in reported general payments places this provider in the 90th percentile of 980 acute care providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $321,968 |
| VerzenioAbemaciclib | 11 | $163,464 |
| Exemestane | 21 | $2,412 |
| Anastrozole | 57 | $870 |
| Entecavir | 13 | $590 |
| Gabapentin | 24 | $213 |
| Alendronate Sodium | 19 | $180 |
| Prochlorperazine Maleate | 11 | $140 |
| Ondansetron OdtOndansetron | 24 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $60 | $321,96820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 980 acute care providers in New York.
Other acute care in New York
- Daniel VerinaNew York$464K
- Katie WorthingtonNew York$25K
- Loveth AdenugaNew York$20K
- Katherine DukeNew York$18K
- Julie Anne RoldanNew York$10K
- Lauren Dela CruzNew York$9K
- Kristen DonchezNew York$8K
- Tracy Valerie BertizNew York$7K
- Jennifer UllmanNew York$7K
- Sara-Jane DakroubNew York$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.